006; p = 0 005), TNM stage (p < 0 001; p < 0 001), and high CXCR4

006; p = 0.005), TNM stage (p < 0.001; p < 0.001), and high CXCR4 expression (p = 0.006; p = 0.01) proved to be significant predictors for poor PXD101 disease free and overall survival respectively, using univariate analyses (Table 1). The Kaplan-Meier curve for disease free survival plotting high versus low expression of CXCR4 is shown in Fig. 1. High expression of CXCR4 retained its strength as independent predictor NVP-HSP990 ic50 of decreased prognosis in disease free survival (HR: 2.0, p = 0.03;

Table 1). Also, TNM stage (HR: 2.9, p = 0.001; HR: 3.1, p = 0.001) retained its strength as independent predictors for disease free and overall survival, while patient age (HR: 2.0, p < 0.05) was found to be an independent predictor only for overall survival. Our RT-PCR results showed that high expression of CXCR4 is independently associated with

poor disease free survival for colorectal cancer patients. Fig. 1 Correlation between disease free survival and expression of CXCR4 assessed by RT-PCR in a cohort of colorectal cancer patients.Kaplan Meier survival curve is displayed. Patients with low expression of CXCR4 had a significant (p = 0.006) increased disease free survival see more compared to patients with high expression of CXCR4 Table 1 High RNA level of CXCR4 is associated with decreased survival Patient characteristics CXCR4 expression Relation CXCR4 to: Disease free survival Overall survival   M-W Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis High N = 35 Low N = 35   p-value HR (95% CI) p-value p-value HR (95% CI) p-value Ureohydrolase Gender Male (%) 19 (54%) 16 (46%) 0.48 0.8     1.0     Female (%) 16 (46%) 19 (54%)               Location tumor Proximal (%) 18 (51%) 18 (51%) 1 0.5     0.5     Distal (%) 17 (49%) 17 (49%)               Median age at diagnosis (years) <68.5 15 (43%) 20 (57%) 0.2 0.006 1.8 0.06 0.005 2.0 <0.05 >68.5 20 (57%) 15 (43%)     1.0–3.5     (1.0–3.9)   TNM stage I and II 24 (69%) 23 (66%) 0.8 <0.001 2.9 0.001 <0.001 3.1 0.001 III 11 (31%) 12 (34%)     (1.6–5.5)     (1.6–6.0)   Pathway MSI 29 (83%) 29 (83%) 1 0.6     0.5     MSS 6 (17%) 6 (17%)               CXCR4 High

      0.006 2.0 0.03 0.01 1.8 0.07 Low         (1.1–3.7)     (1.0–3.6)   Clinicopathological characteristics and survival results of patients with high and low RNA level of CXCR4. Level of CXCR4 was determined in an independent panel colorectal cancer patients. The table displays data of the cohort, as described in materials and methods, using quantitative RT-PCR to determine the level of CXCR4. The 50th percentile was used to define high versus low expression of CXCR4. On the left side of the table the distribution of high versus low expression of CXCR4 with respect to clinical and pathological characteristics and the relation of CXCR4 to clinicopathological factors are displayed. On the right side of the table, prognostic factors are displayed.

No related posts.

Comments are closed.